- Late-breaking CBO421 data demonstrates improved efficacy compared to oleclumab in human triple-negative breast cancer cell lines SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results